Adenosine A2B Receptor Antagonists for Pruritus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipruritic drugs, particularly for chronic pruritus, have limited efficacy, and there is a lack of established drug targets for pruritus, which complicates the development of effective treatments for conditions like uremic, chronic, and acute pruritus.
Innovation Solution
Targeting the adenosine A2B receptor with inhibitors such as the antagonist PSB-603 to block its activity, which is involved in the regulation of pruritus, as indicated by single-cell RNA sequencing data and scratching behavioral experiments, to develop drugs for the prevention and treatment of pruritus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antihistamine drugs are used for treating chronic pruritus, then the treatment approach is simple and well-established, but the efficacy is limited and insufficient for most patients
Solution Approach 1:
The patent changes the therapeutic parameter from targeting histamine H1 receptors to targeting adenosine A2B receptors. This parameter change enables the treatment to be effective across multiple pruritus types (uremic, chronic, acute) rather than being limited to histamine-mediated itch, thereby improving both efficacy and adaptability simultaneously
Solution Approach 2:
The adenosine A2B receptor antagonist PSB-603 demonstrates universal efficacy across different pruritus conditions including uremic pruritus, chronic pruritus, and acute pruritus. This multi-functional approach allows a single drug target to address various forms of pruritus that were previously treated with different mechanisms, resolving the contradiction between efficacy and adaptability
2Reliability
If new drug targets are explored for pruritus, then the treatment efficacy may be improved, but the development complexity and time required increase
Solution Approach 1:
The patent uses single-cell RNA sequencing data as an intermediary to identify the adenosine A2B receptor as a potential target. This intermediary approach allows systematic exploration of drug targets through molecular biology data before moving to preclinical testing, thereby reducing the overall development complexity and time required while maintaining high efficacy potential
Solution Approach 2:
The patent replaces traditional trial-and-error drug discovery methods with a data-driven approach using single-cell RNA sequencing and bioinformatic analysis. This substitution of mechanical/experimental exploration with digital/data-based identification simplifies the initial target selection process and reduces development complexity while ensuring efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Blocking the adenosine A2B receptor with PSB-603 effectively reduces histamine- and chloroquine-induced scratching behaviors, demonstrating its potential as a drug target for treating various forms of pruritus, including uremic and chronic pruritus.
Implementation Method 1
the adenosine A2B receptor as a target in drugs for prevention and/or treatment of pruritus... blocking adenosine A2B receptor activity... the antagonist of the adenosine A2B receptor includes PSB-603
Data Source
AI summary
The present disclosure provides the use of an adenosine A2B receptor as a target in drugs for prevention and/or treatment of pruritus and belongs to the technical field of biological pharmaceuticals. Expression of genes encoding major ligand-gated ion channels is detected based on previously reported single-cell RNA sequencing data of mouse dorsal root ganglions (DRGs), and Adora2b is detected to be highly expressed in Neuron_10, suggesting that Adora2b and Adora2b receptor (the adenosine A2B receptor) may be involved in pruritus regulation. Experimental results show that histamine-induced mouse scratching behavior can be effectively prevented by blocking adenosine A2B receptor activity, indicating that the adenosine A2B receptor is involved in histamine-induced pruritus. The present disclosure further provides the use of a reagent for inhibiting biological functions of an adenosine A2B receptor in preparing drugs for the prevention and/or treatment of pruritus, providing a new means for the prevention and treatment of pruritus.